Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical-induced clastogenicity in chinese hamster V79 cells

Environmental and Molecular Mutagenesis

Volumn 35, Issue 1, 2000, Pages 13-21

  Snyder, Ronald D ^a,b  

^a ABBOTT LABORATORIES   (United States)

^b DUPONT COMPANY   (United States)

Author keywords

Clastogenicity; Clinafloxacin; Etoposide; Interca lation; Micronucleus; Topoisomerase; V79

Indexed keywords

2 AMINOANTHRACENE; 2 FLUORO 1 (3 NORVALYLAMINO 1 PYRROLIDINYL) 4 OXO 4H QUINO[8,1A,1 B,C][1,4]BENZOXAZINE 5 CARBOXYLIC ACID; ACLARUBICIN; AMINOACRIDINE; BLEOMYCIN; CHLOROQUINE; CLASTOGEN; CLINAFLOXACIN; DOUBLE STRANDED DNA; ETHIDIUM BROMIDE; ETOPOSIDE; GYRASE INHIBITOR; HYDROXYUREA; IMIPRAMINE; INTERCALATING AGENT; NOVOBIOCIN; PROMETHAZINE; SODIUM AZIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STRAIN V 79; CHROMOSOME BREAKAGE; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; DNA REPLICATION; DNA STRAND BREAKAGE; DNA TEMPLATE; DRUG DNA INTERACTION; DRUG SAFETY; ENZYME INHIBITION; GENOTOXICITY; MICRONUCLEUS; MUTAGENICITY; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; CATALYSIS; CELL LINE; CRICETINAE; CRICETULUS; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; MUTAGENS;

EID: 0034003770     PISSN: 08936692     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2280(2000)35:1<13::AID-EM3>3.0.CO;2-1     Document Type: Article

References (30)

1. Andoh T, Ishida R. 1998. Catalytic inhibitors of topoisomerase II. Biochim Biophys Acta 1400:155-171.
2. Baguley BC, Ferguson LR, Denny WA. 1982. DNA binding and growth inhibitory properties of a series of 2,7-dialkyl-substituted derivatives of proflavine. Chem Biol Interact 42:97-108.
3. Chu DTW, Hallas R, Clement JJ, Alder J, McDonald E, Plattner JJ. 1992. Synthesis and antitumor activities of quinolone antineoplastic agents. Drugs Exp Clin Res XVIII:275-282.
4. Curry PT, Kropko ML, Garvin JR, Fiedler RD, Theiss JC. 1996. In vitro induction of micronuclei and chromosome aberrations by quinolones: possible mechanisms. Mutat Res 352:142-150.
5. Denny WA. 1989. DNA intercalating ligands as anti-cancer drugs: prospect for future design. Anticancer Drug Des 4:241-263.
6. Fenech M, Morley AA. 1985. Measurement of micronuclei in human lymphocytes. Mutat Res 147:29-36.
7. Ferguson LR. 1998. Inhibitors of topoisomerase II enzymes: a unique group of environmental mutagens and carcinogens. Mutat Res 400:271-278.
8. Ferguson LR, Baguley BC. 1996. Mutagenicity of anticancer drugs that inhibit topoisomerase enzymes. Mutat Res 355:91-101.
9. Fortune JM, Osheroff N. 1998. Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage. J Biol Chem 273:17643-17650.
10. Haldane A, Finlay GJ, Baguley BC. 1993. A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II directed cytotoxic drugs. Oncol Res 5:133-138.
11. Hasinoff BB, Yalowich JC, Ling Y, Buss JL. 1996. The effect of dezroxazane (ICRF-187) on doxorubicin- and daunomycin-mediated growth inhibition of Chinese hamster ovary cells. Anticancer Drugs 7:558-567.
12. Ishida R, Iwai M, Hara A, Andoh T. 1996. The combination of different types of antitumor topoisomerase II inhibitors, ICRF-193 and VP-16, has synergistic and antagonistic effects on cell survival, depending on treatment schedule. Anticancer Res 16:2735-2740.
13. Jensen PB, Sehested M. 1997. DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide. Biochem Pharmacol 54:755-759.
14. Jensen PB, Jensen PS, Demant EJF, Friche E, Sorensen BS, Sehested M, Wassermann K, Vindeloev L, Westergaard O, Hansen HH. 1991. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res 51:5093-5099.
15. Jensen PB, Sorensen BS, Demant EJF, Sehested M, Jensen PS, Vindelov L, Hansen HH. 1990. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res 50:3311-3316.
16. Jensen PB, Sorensen BS, Sehested M, Grue P, Demant EJF, Hansen HH. 1994. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments. Cancer Res 54:2959-2963.
17. Kano Y, Narita T, Suzuki K, Akutsu M, Suda K, Sakamoto S, Miura Y. 1992. The effects of ICRF-154 in combination with other anticancer agents. Br J Cancer 66:281-286.
18. Nelson EM, Tewey KM. Liu LF. 1984. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci USA 81:1361-1365.
19. Osheroff N, Shelton ER, Brutlag DL. 1983. DNA topoisomerase II from Drosnphila melanogaster: relaxation of supercoiled DNA. J Biol Chem 258:9536-9543.
20. Permana PA, Snapka RM, Shen LL, Chu DTW, Clement JJ, Plattner JJ. 1994. Quinobenoxazines: a class of novel antitumor quinolones and potent mammalian DNA topoisomerase II catalytic inhibitors. Biochemistry 33:11333-11339.
21. Ross WE, Bradley MO. 1981. DNA double-strand breaks in mammalian cells after exposure to intercalating agents. Biochim Biophys Acta 654:129-134.
22. Rowe T, Kupfer G, Ross WE. 1985. Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage. Biochem Pharmacol 34:2483-2487.
23. Sehested M, Jensen PB, Sorensen BS, Holm B, Friche E. Demant EJF. 1993. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 46:389-393.
24. Snyder RD. 1998. A review and investigation into the mechanistic basis of the genotoxicity of antihistamines. Mutat Res 411:235-248.
25. Snyder RD, Cooper CS. 1999. Photogenotoxicity of fluoroquinolones in Chinese hamster V79 cells: dependency on active topoisomerase II. Photochem Photobiol 69:288-293.
26. Snyder RD, Strekowski L. 1999. Enhancement of bleomycin-induced micronucleus formation in V79 cells as a rapid and sensitive screen for non-covalent DNA binding compounds. Mutat Res in press.
27. Strekowski L. 1992. Molecular basis for the enhancement and inhibition of bleomycin-mediated degradation of DNA by DNA-binding compounds. Adv Detail React Mech 2:61-109.
28. Strekowski L, Wilson WD, Mokrosz JL, Mokrosz MJ, Harden DB, Tanious FA, Wydra RL, Crow SA. 1991. Quantitative structure-activity relationship analysis of cation-substituted polyaromatic compounds as potentiators (amplifiers) of bleomycin-mediated degradation of DNA. J Med Chem 34:580-588.
29. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. 1984. Adriamycininduced DNA damage mediated by mammalian DNA topoisomerase II. Science 226:466-468.
30. Wilson WR, Harris NM, Ferguson LR. 1984. Comparison of the mutagenic and clastogenic activity of amsacrine and other DNA-intercalating drugs in cultured V79 Chinese hamster cells. Cancer Res 44:4420-4431.